Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,628 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

NCT04896086
View directory record Official record
Conditions
Influenza, Seasonal Influenza
Interventions
VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

NCT00809250
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
Interventions
GM-K562/leukemia cell vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women

NCT02375113
View directory record Official record
Conditions
Central Obesity
Interventions
soy supplementation
Dietary Supplement
Lead sponsor
The University of Texas at San Antonio
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 29, 2026, 10:57 AM EDT
Recruiting Not applicable Interventional

Supporting Evidence-based Responses to Emotional Needs in Emphysema

NCT06600126
View directory record Official record
Conditions
COPD
Interventions
Coping Skills Training, COPD Education
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fiber Mix and Glycemic Response

NCT03334643
View directory record Official record
Conditions
Type2 Diabetes Mellitus
Interventions
Fiber mix
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Comparing TAP Blocks Bupivacaine, and Placebo for Plane

NCT04685876
View directory record Official record
Conditions
Abdominal Surgery
Interventions
Liposomal bupivacaine, Plain bupivacaine, Normal saline
Drug
Lead sponsor
Edward Mascha
Other
Eligibility
18 Years to 85 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 29, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

NCT01875653
View directory record Official record
Conditions
Stage IV Melanoma, Stage III Melanoma
Interventions
Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 29, 2026, 10:57 AM EDT
Completed No phase listed Observational Results available

Pediatric Language and Memory Mapping in Refractory Epilepsy Using Magnetoencephalography

NCT04888637
View directory record Official record
Conditions
Epilepsy
Interventions
Baseline MEG Test, Receptive Language Task, Memory Task
Diagnostic Test · Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
8 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Novel Adjuvants for Peptide-Based Melanoma Vaccines

NCT00028431
View directory record Official record
Conditions
Melanoma
Interventions
MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 29, 2026, 10:57 AM EDT
Not listed Not applicable Interventional

Pain and Opioid Management in Older Adults

NCT05037682
View directory record Official record
Conditions
Pain, Chronic, Opioid Use Disorder
Interventions
Dissemination and Implementation Research
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Safety of a Novel Milk Protein Peptide

NCT01412658
View directory record Official record
Conditions
Drug Safety
Interventions
Hydrolyzed milk protein mixture, Glycerol placebo
Dietary Supplement
Lead sponsor
Ambryx Biotechnology
Industry
Eligibility
35 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00036790
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, motexafin gadolinium
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 29, 2026, 10:57 AM EDT
Withdrawn Phase 4 Interventional

Vaginal Cuff Infiltration With Liposomal Bupivacaine for Pain Relief: A Double Blind, Randomized Controlled Trial

NCT05823363
View directory record Official record
Conditions
Postoperative Pain
Interventions
Exparel with Bubivacaine, Bupivacaine only
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Experiment 3: Mixed vs Blocked; Dashboard Paradigm

NCT06934213
View directory record Official record
Conditions
Vision, Healthy, Attention
Interventions
Choice, Mixed trials
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Not applicable Interventional Results available

The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)

NCT02072148
View directory record Official record
Conditions
Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma
Interventions
PET/CT, Radiotherapy, Concurrent Chemoradiation
Procedure · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Flavonoids and Caffeine Supplementation on Resting Metabolism

NCT03752125
View directory record Official record
Conditions
Diet Modification
Interventions
Flavonoid, caffeine, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
20 Years to 47 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 29, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR

NCT00334347
View directory record Official record
Conditions
Mania, Mixed Mania
Interventions
Depakote ER, Depakote DR
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 29, 2026, 10:57 AM EDT
Recruiting Not applicable Interventional

Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy

NCT07220590
View directory record Official record
Conditions
Cerebral Palsy Children, Motor Disabilities, Developmental Disability, Rehabilitation, Early Intervention, Assistive Technology
Interventions
Therapist Training on Powered Mobility Implementation, Powered Mobility Intervention for Child-Caregiver Dyads
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
12 Months and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Hillsboro, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks

NCT05820490
View directory record Official record
Conditions
Metabolic Health
Interventions
Whole Room Calorimeter, Mixed-Meal Tolerance Test (MMTT), Core Body Temperature, Morningness-Eveningness Questionnaire, Muscle Biopsy, Serial Blood Sampling
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 29, 2026, 10:57 AM EDT
Enrolling by invitation Not applicable Interventional

Use of Augmented Reality and Virtual Reality During Cognitive Behavioral Therapy for Needle Phobia

NCT07042074
View directory record Official record
Conditions
Needle Phobia, Virtual Reality, Cognitive Behavior Treatment
Interventions
Mixed reality (XR) Exposure Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
11 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913
View directory record Official record
Conditions
Mania, Bipolar Disorder
Interventions
Xanomeline/Trospium Chloride, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 29, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

NCT00865280
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
PTK 0796, linezolid, moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 29, 2026, 10:57 AM EDT